Pipeline
The Best Target & The Best Chemical
PHI-101-RS is a drug that is being developed as a radiation sensitizer through an indication expansion analysis using Pharos iBio's big data & AI-based new drug development platform. It can be taken at the same time when cancer patients receive radiation therapy to improve the efficiency of radiation treatment to cancer tissues, so that the same effect can be obtained with a small amount of radiation, while reducing damage to normal cells.
-
About 40% of all cancer
patients are treated with
radiation -
Erbitux, approved for
combination with radiation,
sold $1.15B USD in 2012 in
head and neck cancer
In the in vivo Xenograft model of colorectal cancer, the radiation combination efficacy was increased by 2-3 times compared to the control group
- Colorectal cancer invivo results
-
-
Number of patients 40% of cancer patients
-
Market size KRW 1.2T (2023) Target Market
- HPV- or HPV- & CD44+ positive patients
- Non-Hypoxic patients
Source : Market size-Reuters, Jun 1 2013, Number of patients-Acta Oncol. 42, 357-365 (2003)